A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)

PHASE1TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Chronic Heart Failure
Interventions
DRUG

BAY2413555 Dose 1

BAY2413555 Dose 1

DRUG

BAY2413555 Dose 2

BAY2413555 Dose 2

DRUG

Placebo to BAY2413555

Placebo to BAY2413555

Trial Locations (18)

5000

Odense Universitetshospital, Hjertemedicinsk Amb., Odense C

17011

Capital Area Research, LLC, Camp Hill

20904

White Oak Medical Center, Silver Spring

30342

Accel Research Sites - Atlanta Clinical Research Center, Atlanta

46014

Hospital General Universitario de Valencia, Valencia

Unknown

"Capital Region , Gentofte Hospital - Cardiology Research"

"Zealand University Hospital , Roskilde - Cardiology Department"

"Barzilai Ashkelon University Medical Center , Cardiology Department"

"Rambam Health Care Campus , Internal Medicine - Cardiology Department"

"Ziv Medical Center , Cardiology Department"

"Hospital del Mar , Cardiology Department"

"Hospital Universitari de Bellvitge , Bellvitge Biomedical Research Institute - Cardiology Department"

"Junta de Andalucía , University Hospital Reina Sofia - Cardiology Department"

"Hospital Universitario Virgen de la Victoria , Cardiology Department"

Saxony

"Pratia , Klinische Forschung Dresden"

Lombardy

"Humanitas Research Hospital , Cardio Center - Clinical, Interventional Cardiology and Coronary Care"

Tuscany

"Fondazione Toscana Gabriele Monasterio , Heart Hospital Gaetano Pasquinucci - Cardiology Department"

Pontevedra

"Hospital Alvaro Cunqueiro , Cardiology Department"

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05532046 - A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT) | Biotech Hunter | Biotech Hunter